Saturday, March 27, 2021 3:33:32 AM
So it would appear they do have just enough money to make it to the end of the year. But only just.
They had 8.26 million as of Dec 31 2020. Then got 5 million, so 13.26 million.
They had a burn last year of about 4 million per quarter. Giving them 1.26 million expected at end Dec 31 2021.
They also expect R&D costs to go up in 2021 vs 2020, so probs just just enough money to get them to December.
Does anybody have ok communications with CANF IR, ask them how things are going with the Piclidenoson recruitment? I believe Topline data was slated for end of year 2021. They mentioned spending considerable funds on "accelerating rate of absorption of patients for the Phase III clinical trial of Piclidenoson".
If we don't hear about the rate of enrollment then this likely gets delayed as they have been epically slow on recruitment.
If however they are recruiting well then that could turn the tides on deciding to invest.
They had 8.26 million as of Dec 31 2020. Then got 5 million, so 13.26 million.
They had a burn last year of about 4 million per quarter. Giving them 1.26 million expected at end Dec 31 2021.
They also expect R&D costs to go up in 2021 vs 2020, so probs just just enough money to get them to December.
Does anybody have ok communications with CANF IR, ask them how things are going with the Piclidenoson recruitment? I believe Topline data was slated for end of year 2021. They mentioned spending considerable funds on "accelerating rate of absorption of patients for the Phase III clinical trial of Piclidenoson".
If we don't hear about the rate of enrollment then this likely gets delayed as they have been epically slow on recruitment.
If however they are recruiting well then that could turn the tides on deciding to invest.
Recent CANF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2026 11:05:55 AM
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy • GlobeNewswire Inc. • 05/13/2026 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/30/2026 12:34:19 PM
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months • GlobeNewswire Inc. • 04/30/2026 12:31:35 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/23/2026 08:15:11 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 11:59:42 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/06/2026 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/03/2026 09:07:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:22:12 AM
- Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 • GlobeNewswire Inc. • 03/30/2026 11:20:00 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/26/2026 02:05:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 01:29:33 PM
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient • GlobeNewswire Inc. • 03/26/2026 01:27:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/17/2026 11:50:36 AM
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance • GlobeNewswire Inc. • 03/17/2026 11:47:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 08:30:01 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/05/2026 12:31:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 12:29:04 PM
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds • GlobeNewswire Inc. • 03/04/2026 03:25:41 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 12:05:05 PM
- Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/17/2026 12:01:59 PM
